Psilocybin (MYCO-001) for PTSD in Veterans

Mydecine has announced they will be conducting a Phase IIa study investigating the effects of psilocybin-assisted psychotherapy in the treatment of PTSD in veterans.

The trial will use MYCO-001, Mydecine’s proprietary naturally derived psilocybin formulation.

Topic PTSD

Compound Psilocybin

Country United States of America

Visit trial

Trial Details

Trial Number

Sponsors & Collaborators

Mydecine
Mydecine (Mydecine Innovations Group Inc.) is the parent organization of Mindleap, Mydecine Health Sciences, and NeuroPharm.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.